New REDUCE-IT Analysis Reinforces Vascepa's Role in Identifying High-Risk Patients
AMRN sits 46% above its 52-week low of $10.85.
Summary
This news highlights a new post hoc analysis from the pivotal REDUCE-IT trial, presented at the European Atherosclerosis Society Congress. The analysis suggests that Risk-Weighted ApoB can more effectively identify statin-treated patients with hypertriglyceridemia who remain at increased cardiovascular risk. This finding is positive for Amarin's drug, Vascepa (icosapent ethyl), as it reinforces the drug's utility and could help expand the identification of patients who may benefit from additional intervention. The article also notes recent guideline updates from ESC/EAS and ACC/AHA/Multisociety that support the evolving role of IPE in reducing cardiovascular risk. This clinical reinforcement comes after shareholders recently rejected proposals for equity issuance, making positive product news particularly important.
At the time of this announcement, AMRN was trading at $15.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $300M. The 52-week trading range was $10.85 to $20.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.